Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Cabometyx and Kisplyx provide additional treatment options for patients with renal cell carcinoma

bs_subtitle

The European Medicines Agency (EMA) has recommended granting marketing authorisations in the European Union (EU) for two medicines for the treatment of advanced renal cell carcinoma. Cabozantinib (Cabometyx) and lenvatinib (Kisplyx) are indicated for the treatment of adult patients with advanced renal cell carcinoma who have been previously treated with a vascular endothelial growth factor (VEGF)-inhibitor; cabozantinib is to be used as monotherapy while lenvatinib is for use in combination with everolimus. Renal cell carcinoma is the most common form of kidney cancer in adults. Advanced renal cell carcinoma includes both metastatic disease and locally advanced renal cell carcinoma that

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy